Mini-series: II. Clinical aspects. Clinically relevant CYP450-mediated drug interactions in the ICU

Intensive Care Medicine

Volumn 35, Issue 4, 2009, Pages 603-612

  Spriet, Isabel ^a   Meersseman, Wouter ^a   De Hoon, Jan ^a   Von Winckelmann, Sandrina ^a   Wilmer, Alexander ^a   Willems, Ludo ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

CYP450; Drug drug interactions; ICU; Induction; Inhibition

Indexed keywords

ANTIFUNGAL AGENT; AZITHROMYCIN; CARBAMAZEPINE; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; ERYTHROMYCIN; FENTANYL; FLUCONAZOLE; HYDROCORTISONE; ITRACONAZOLE; MACROLIDE; METHYLPREDNISOLONE; MIDAZOLAM; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; PHENOBARBITAL; PHENYTOIN; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TACROLIMUS; UNINDEXED DRUG; VERAPAMIL; VORICONAZOLE; WARFARIN;

ATRIOVENTRICULAR JUNCTION ARRHYTHMIA; BLEEDING; COMA; CONFUSION; DELIRIUM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENCY; DRUG SUBSTITUTION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTENSION; INTENSIVE CARE UNIT; KIDNEY FAILURE; MEDICAL EDUCATION; MEDICAL PRACTICE; NEPHROTOXICITY; NEUROLOGIC DISEASE; QT PROLONGATION; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; SUDDEN DEATH; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ANALGESICS, OPIOID; ANTI-BACTERIAL AGENTS; ANTICONVULSANTS; BENZODIAZEPINES; CATECHOLAMINES; CHRONIC DISEASE; CRITICAL CARE; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTENSIVE CARE UNITS; MIDAZOLAM; TACROLIMUS;

EID: 62949188919     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-008-1383-2     Document Type: Review

References (76)

1. BJ Kopp BL Erstad ME Allen AA Theodorou G Priestley 2006 Medication errors and adverse drug events in an intensive care unit: direct observation approach for detection Crit Care Med 34 415 425
2. V Krishnan P Murray 2003 Pharmacologic issues in the critically ill Clin Chest Med 24 671 688
3. Baxter K, Stockley IH (2006) Stockley's drug interactions, 7th edn. Pharmaceutical Press, London
4. LL Leape DJ Cullen M Dempsey Clapp E Burdick HJ Demonaco J Ives Erickson DW Bates 1999 Pharmacist participation on physician rounds and adverse drug events in the intensive care unit JAMA 281 267 270
5. A Rivkin 2007 Admission to a medical intensive care unit related to adverse drug reactions Am J Health Syst Pharm 64 1840 1843
6. MJ Ellenhorn FA Sternad 1996 Problems of drug interactions J Am Pharmacol Assoc NS 6 62 68
7. M Pirmohamed BK Park 2003 Cytochrome P450 enzyme polymorphisms and adverse drug reactions Toxicol 192 23 32
8. HJ Mann 2006 Drug-associated disease: cytochrome P450 interactions Crit Care Clin 22 329 345
9. GR Wilkinson 2005 Drug metabolism and variability among patients in drug response N Engl J Med 352 2211 2221
10. DF Lewis 2004 57 varieties: the human cytochromes P450 Pharmacogenom 5 305 318
11. JH Lin AYH Lu 1998 Inhibition and induction of cytochrome P450 and the clinical implications Clin Pharmacokinet 35 361 390
12. KM Kulmatycki F Jamali 2005 Drug disease interactions: role of inflammatory mediators in disease and variability in drug response J Pharm Pharmaceut Sci 8 602 625
13. KW Renton 2004 Cytochrome P450 regulation and drug biotransformation during inflammation and infection Curr Drug Metab 5 235 243
14. K Venkatakrishnan LL von Moltke DJ Greenblatt 2000 Effects of the antifungal agents on oxidative drug metabolism Clin Pharmacokinet 38 111 180
15. M Niemi JT Backman MF Fromm PJ Neuvonen KT Kivistö 2003 Pharmacokinetic interactions with rifampicin. Clinical relevance Clin Pharmacokinet 42 819 850
16. CK Finch CR Chrisman AM Baciewicz TH Self 2002 Rifampin and rifabutin drug interactions. An update Arch Intern Med 162 985 992
17. LB Gerson G Triadafilopoulos 2001 Proton pump inhibitors and their drug interactions: an evidence-based approach Eur J Gastroenterol Hepatol 13 611 616
18. D Czock F Keller FM Rasche U Häussler 2005 Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids Clin Pharmacokinet 44 61 98
19. E Tanaka 1999 Clinically significant pharmacokinetic drug interactions between anti-epileptic drugs J Clin Pharm Ther 24 87 89
20. E Perucca 2005 Clinically relevant drug interactions with antiepileptic drugs Br J Clin Pharmacol 61 246 255
21. MP Pai KM Momary KA Rodvold 2006 Antibiotic drug interactions Med Clin N Am 90 1223 1255
22. AH Saad D DePestel P Carver 2006 Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants Pharmacotherapy 26 1730 1744
23. Cozza KL, Armstrong SC, Oesterheld JR (2003) Concise guide to drug interaction principles for medical practice, 2nd edn. American Psychiatric Publishing, Washington, DC
24. GK Dresser JD Spence DG Bailey 2000 Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition Clin Pharmacokinet 38 41 57
25. MM Doherty WH Charman 2002 The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism Clin Pharmacokinet 41 235 253
26. JT Backman KT Kivistö KT Olkkola PJ Neuvonen 1998 The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin Eur J Clin Pharmacol 54 53 58
27. KT Olkkola J Ahonen PJ Neuvonen 1996 The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam Anesth Analg 82 511 516
28. U Theuretzbacher F Ihle H Derendorf 2006 Pharmacokinetic/pharmacodynamic profile of voriconazole Clin Pharmacokinet 45 649 663
29. JC Gorski DR Jones BD Haehner-Daniels MA Hamman EM O'Mara SD Hall 1998 The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin Clin Pharmacol Ther 64 133 143
30. RA Yeates H Laufen T Zimmermann 1996 Interaction between midazolam and clarithromycin: comparison with azithromycin Int J Clin Pharmacol Ther 34 400 405
31. J Ahonen KT Olkkola A Takala PJ Neuvonen 1999 Interaction between fluconazole and midazolam in intensive care patients Acta Anaesthesiol Scand 43 509 514
32. JT Backman KT Olkolla M Ojala H Laaksovirta PJ Neuvonen 1996 Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin Epilepsia 37 253 257
33. JT Backman KT Olkkola PJ Neuvonen 1996 Rifampin drastically reduces plasma concentrations and effects of oral midazolam Clin Pharmacol Ther 59 7 13
34. JP Kress AS Pohlman MF O'Connor JB Hall 2000 Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation N Engl J Med 342 1471 1477
35. HL Leather 2004 Drug interactions in the hematopoetic stem cell transplant (HSCT) recipient: what every transplanter needs to know Bone Marr Transplant 33 137 152
36. U Christians W Jacobsen LZ Benet A Lampen 2002 Mechanisms of clinically relevant drug interactions associated with tacrolimus Clin Pharmacokinet 41 813 851
37. RB Ibrahim EM Abella PH Chandrasekar 2002 Tacrolimus-clarithromycin interaction in a patient receiving bone marrow transplantation Ann Pharmacother 36 1971 1972
38. C Jensen M Jordan R Shapiro V Scantlebury T Hakala J Fung T Starzl R Venkataramanan 1994 Interaction between tacrolimus and erythromycin Lancet 344 825
39. DL Paterson N Singh 1997 Interactions between tacrolimus and antimicrobial agents Clin Infect Dis 25 1430 1440
40. Vfend (voriconazole) package insert. Pfizer Inc. January 2006
41. AJ Romero PL Pogamp LG Nilsson N Wood 2002 Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients Clin Pharmacol Ther 71 226 234
42. DM Canafax NM Graves DM Hilligoss BC Carleton MJ Gardner AJ Matas 1991 Interaction between cyclosporine and fluconazole in renal allograft recipients Transplantation 51 1014 1018
43. JM Aguado JA Herrero J Gavalda J Torre-Cisneros M Blanes G Rufi A Moreno A Gurgui M Hayek C Lumbreras and the Spanish Transplantation Infection Study Group, GESITRA 1997 Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain Transplantation 63 1276 1286
44. Z Karasu A Gurakar J Carlson S Pennington B Kerwin H Wright B Nour A Sebastian 2001 Acute tacrolimus overdose and treatment with phenytoin in liver transplant recipients J Okla State Med Assoc 94 121 123
45. GE McLaughlin M Gonzalez-Rossique B Gelman T Kato 2000 Use of phenobarbital in the management of acute tacrolimus toxicity: a case report Transplant Proc 32 665 668
46. SC Armstrong KL Cozza 2003 Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part I Psychosomatics 44 167 171
47. SC Armstrong L Cozza 2003 Pharmacokinetic drug interactions of morphine, codeine and their derivatives: theory and clinical reality, Part II Psychosomatics 44 515 520
48. ML Buck JL Blumer 1991 Opioids and other analgesics. Adverse effects in the intensive care unit Crit Care Clin 7 615 637
49. VJ Palkama PJ Neuvonen KT Olkolla 1998 The CYP3A4 inhibitor itraconazole has no effect on the pharmacokinetics and pharmacodynamics of i.v. fentanyl Br J Anaesth 81 598 600
50. R Tempelhoff P Modica E Spitznagel 1988 Increased fentanyl requirement in patients receiving long-term anticonvulsant therapy Anesthesiology 69 A594
51. R Beers E Camporesi 2004 Remifentanil update: clinical science and utility CNS Drugs 18 1085 1104
52. H Linthoudt D Van Raemdonck T Lerut M Demedts G Verleden 1996 The association of itraconazole and methylprednisolone may give rise to important steroid-related side effects J Heart Lung Transplant 15 1165
53. M Bartoszek AM Brenner SJ Szefler 1987 Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy Clin Pharmacol Ther 42 424 432
54. WA Ray KT Murray S Meredith SS Narasimhulu K Hall CM Stein 2004 Oral erythromycin and the risk of sudden death from cardiac causes N Engl J Med 351 1089 1096
55. BA Liu DN Juurlink 2004 Drug and the QT interval-Caveat Doctor N Engl J Med 351 1053 1056
56. RJ Wallace BA Brown DE Griffith W Girard K Tanaka 1995 Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection J Infect Dis 171 747 750
57. S Telt D Carey HS Lee 1992 Drug interactions with fluconazole Med J Aust 156 365
58. RA Blum JH Wilton DM Hilligoss MJ Gardner EB Henry NJ Harrisson JJ Schentag 1991 Effect of fluconazole on the disposition of phenytoin Clin Pharmacol Ther 49 420 425
59. DA Flockhart JE Tanus-Santos 2002 Implications of cytochrome P450 interactions when prescribing medication for hypertension Arch Intern Med 162 405 412
60. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 1 December 2007. Developed by the DHHS Panel on antiretroviral guidelines for adults and adolescents-a working group of the office of AIDS research advisory council (OARAC). Available from: http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. Accessed on: 15 January 2008
61. DM Burger PL Meenhorst JW Mulder CL Kraaijeveld CHW Koks A Bult JH Bijnen 1994 Therapeutic drug monitoring of phenytoin in patients with the acquired immunodeficiency syndrome Ther Drug Monit 16 616 620
62. GT Blyden JM Scavone DJ Greenblatt 1988 Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam J Clin Pharmacol 28 240 245
63. L Kay JP Kampmann TL Svendsen B Vergman JEM Hansen L Skovsted M Kristenen 1985 Influence of rifampicin and isoniazid on the kinetics of phenytoin Br J Clin Pharmacol 20 323 326
64. AM Holbrook JA Pereira R Labiris H Mc Donald JD Douketis M Crowther PS Wells 2005 Systematic overview of warfarin and its drug and food interactions Arch Intern Med 165 1095 1106
65. DS Budnitz N Shehab SR Kegler CL Richards 2007 Medication use leading to emergency department visits for adverse drug events in older adults Ann Intern Med 147 755 765
66. NA Limdi DL Veenstra 2008 Warfarin pharmacogenetics Pharmacother 28 1084 1087
67. UI Schwarz MD Ritchie Y Bradford C Li SM Dudek A Frye-Anderson RB Kim DM Roden CM Stein 2008 Genetic determinants of response to warfarin during initial anticoagulation N Engl J Med 358 999 1008
68. US Food and Drug Administration. Warfarin product labelling. Available from http://www.fda.gov/cder/foi/label/2007/009218s105lblv2.pdf Accessed 1 September 2008
69. S Ozawa A Soyama M Saeki H Fukushima-Uesaka M Itoda S Koyano K Sai Y Ohno Y Saito J Sawada 2004 Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1 Drug Metab Pharmacokinet 19 83 95
70. UM Stamer F Stüber T Muders F Musshoff 2008 Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication Anesth Analg 107 926 929
71. Y Gashe Y Daaili M Fathi A Chiappe S Cottini P Dayer J Desmeules 2004 Codeine intoxication associated with ultrarapid CYP2D6 metabolism N Engl J Med 351 2827 2837
72. G Koren J Cairns D Chitayat A Gaedigk SJ Leeder 2006 Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine prescribed mother Lancet 368 704
73. BP Skop TM Brown TR Mareth 1995 The serotonin syndrome associated with paroxetine Am J Emerg Med 13 606 607
74. LA Kroon 2007 Drug interactions with smoking Am J Health Syst Pharm 64 1917 1921
75. Mouly S, Meune C, Bergmann JF (2007) Application and clinical value of in vitro models in predicting CYP-mediated drug-drug interactions in the ICU. I. Basic Science (accepted)
76. US Food and Drug Administration. Center for Devices and Radiological Health consumer information. New device clearance. Roche Amplichip cytochrome P450 genotyping test and Affymetrix GeneChip Microarray Instrumentation System-K042259. Available from: http://www.fda.gov/cdrh/mda/docs/k042259.html Accessed 16 September 2008